Evaluation of factors predicting pathologic complete response in locally advanced HER2 positive breast cancer treated with neoadjuvant pertuzumab, trastuzumab and chemotherapy; Real life data.

Ates, Ozturk; Oksuzoglu, O Berna; Aktas, Burak Yasin; Karadag, Ibrahim; Esen, Selin; Karakaya, Serdar; Uncu, Dogan; Erol, Cihan; Gurbuz, Mustafa; Yalcin, Bulent; Aksoy, Sercan

Ates, Ozturk; Oksuzoglu, O Berna; Aktas, Burak Yasin; Karadag, Ibrahim; Esen, Selin; Karakaya, Serdar; Uncu, Dogan; Erol, Cihan; Gurbuz, Mustafa; Yalcin, Bulent; Aksoy, Sercan.

Affiliation

Ates O; Health Sciences University, Dr. Abdurrahman Yurtaslan, Ankara Oncology Education and Research Hospital, Department of Medical Oncology, Ankara, Turkey.

J BUON ; 26(4): 1398-1404, 2021.

Article in En | MEDLINE | ID: mdl-34564997

Subject(s)

Antibodies, Monoclonal, Humanized/therapeutic use; Antineoplastic Agents, Immunological/therapeutic use; Breast Neoplasms/drug therapy; Breast Neoplasms/pathology; Trastuzumab/therapeutic use; Adult; Aged; Breast Neoplasms/chemistry; Female; Humans; Middle Aged; Neoadjuvant Therapy; Prognosis; Receptor, ErbB-2/analysis; Retrospective Studies; Treatment Outcome; Young Adult

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antibodies, Monoclonal, Humanized / Trastuzumab / Antineoplastic Agents, Immunological Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: J BUON Journal subject: NEOPLASIAS Year: 2021 Document type: Article Affiliation country: Turkey Country of publication: Cyprus

Search on Google

Add to My VHL

XML

PubMed Links